Sign In
Buy TMCI
$3.69
+0.290 (+8.53%)
At Close: Jun 04, 2026
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Saturday, 15'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Thursday, 13'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Tuesday, 11'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace M
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Sunday, 09'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Friday, 07'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
04:15pm, Thursday, 06'th Feb 2025
PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the
LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
11:00am, Wednesday, 05'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Me
